Top Viagra Brands: Unveiling the Leaders in ED Solutions

As discussions about men's health become more open, the topic of erectile dysfunction and its treatments has gained prominence. Viagra, a well-known medication for treating this condition, has seen various brands emerge offering different formulations and price points. Each brand aims to provide effective solutions while ensuring safety and reliability for users. Below, we explore some of the best brands for Viagra, detailing their unique offerings and what sets them apart in the market.

Illustration of viagra

Best brands of viagra in 2025

Pfizer

Pfizer's Viagra remains a dominant force in the erectile dysfunction market despite intense generic competition, with the brand maintaining a significant market share even after losing its patent exclusivity in 2017. In 2020, Viagra reported a 29% increase in Q3 global sales, driven by strong performance in China and other international markets, accounting for 79% of its Q3 sales. The drug has managed to retain 65% of ED prescriptions filled between December 2018 and January 2019, a testament to Pfizer's strategic marketing and brand recognition. Viagra's resilience is also attributed to Pfizer's introduction of its own generic version at half the cost of the branded drug and various discount programs. The Viagra segment held the largest revenue share of 57.3% in the global erectile dysfunction drugs market in 2024.

Teva Pharmaceuticals

Teva Pharmaceuticals is a leading producer of generic Viagra, capitalizing on the expiration of Pfizer's patent in 2017 to launch its own version. In 2020, Teva's generic tadalafil, ALYQ, was also approved, further expanding their ED treatment offerings. Teva's global reach, with over 53 manufacturing facilities in more than 33 countries, enables widespread access to these medications. The company serves approximately 200 million people daily and produces around 76 billion tablets and capsules annually. Teva's involvement in the ED market contributes significantly to the growth of the erectile dysfunction treatment drugs market, expected to grow at a CAGR of 6.84% from 2024 to 2032.

Mylan

Mylan, now part of Viatris, played a significant role in the pharmaceutical industry, although it was not the primary producer of Viagra. Viagra, a drug for erectile dysfunction, was originally developed and marketed by Pfizer, with its patent expiring in the European Union in 2013 and in the U.S. in 2017, leading to a decline in sales by almost 70% between 2012 and 2018. In 2020, Pfizer's off-patent branded and generics business, including Viagra, was spun off and combined with Mylan to form Viatris. Viatris now manages the distribution of Viagra among its extensive portfolio of over 7,500 marketed products. Despite not being the original producer, Viatris continues to be a major player in the global pharmaceutical market. For more information about Viatris and their extensive product portfolio, visit their official newsroom.

Cipla

Cipla, although facing recent regulatory challenges, remains a significant player in the pharmaceutical industry. However, it is not specifically highlighted as a leading producer of Viagra. Viagra, a dominant market leader, is primarily associated with Pfizer, which holds a market share of 31.97% in 2023 and a 58% revenue share in the erectile dysfunction drugs market. For more detailed information about Cipla's offerings and contributions, visit their official website.

Aurobindo Pharma

Aurobindo Pharma is a prominent player in the production of generic Viagra, having received final approval from the USFDA to manufacture and market Sildenafil Tablets in 2015. This approval allowed Aurobindo Pharma to enter the lucrative erectile dysfunction drugs market, where Viagra holds a significant share, with the Viagra segment accounting for 57.3% of the market revenue in 2024. Aurobindo Pharma's generic version of Viagra is bioequivalent and therapeutically equivalent to Pfizer's REVATIO, and it is expected to capitalize on the growing demand for ED treatments, with the global ED drugs market projected to grow at a CAGR of 9.13% from 2025 to 2030. The company's international presence, with exports to over 125 countries, further enhances its market reach. Aurobindo Pharma's revenue from its U.S. drug formulations alone accounts for 48% of its total revenue, highlighting its strong foothold in the global pharmaceutical market.

Sun Pharmaceuticals

Sun Pharmaceutical Industries Limited, although not the primary producer of Viagra, is a significant player in the global pharmaceutical market, particularly in the generic drugs sector. As the fourth largest specialty generic pharmaceutical company worldwide, Sun Pharma generates global revenues of US$ 5.4 billion and has a strong presence in over 100 countries. However, Viagra (sildenafil citrate) is predominantly associated with Pfizer Inc., which holds a dominant market share of around 57-58% in the erectile dysfunction drugs market. Sun Pharma's expertise lies in producing a wide range of generic and specialty pharmaceuticals, but it is not specifically known for producing Viagra. The company's global footprint and extensive product portfolio make it a major force in the pharmaceutical industry. For more information about Sun Pharmaceutical Industries Limited, visit their website.

Lupin Pharmaceuticals

Lupin Pharmaceuticals, one of the world's largest generic pharmaceutical companies, plays a significant role in the production and distribution of generic Viagra (sildenafil citrate). With a global footprint across over 100 countries, Lupin is known for its high-quality and affordable generic formulations, including sildenafil citrate, which has been available in Canada and Europe since 2012 and 2013, respectively. Lupin's generic version of Viagra contributes to the market's growth, particularly after the patent expiration of the branded version in 2020. The company's strong presence in the generics market, where it holds a significant market share in the US, further solidifies its position as a key player in the erectile dysfunction drugs market. Lupin's commitment to research and innovation ensures the continuous development of effective and affordable treatments. For more information about their products, visit Lupin Pharmaceuticals' official website.

Alembic Pharmaceuticals

Alembic Pharmaceuticals is a prominent player in the pharmaceutical industry, though it is not specifically highlighted as a leading producer of Viagra. However, the company is involved in the development, manufacturing, and marketing of various pharmaceutical products, including formulations and active pharmaceutical ingredients. Alembic has a significant presence in the domestic formulations market in India, holding a 1.5% market share and boasting a portfolio of about 200 formulation brands. The company has also been recognized for its innovations, receiving the Thomson Reuters Top 50 Indian Innovators Award in 2015. While it is not a primary producer of Viagra, Alembic's capabilities and market presence make it a notable player in the pharmaceutical sector. For more detailed financial insights, visit their stock profile on Moneycontrol.

Sandoz

Sandoz, the generics unit of Novartis, is not specifically known for producing Viagra, but it has been a significant player in the generics market, including competing with Pfizer's Lyrica. In 2019, Sandoz led the pack with 9.7% of the market share for Lyrica generics, demonstrating its strong presence in the generics sector. However, for Viagra (sildenafil), other companies like Greenstone, a Pfizer subsidiary, have been more involved in its generic production. The global sildenafil market, which includes Viagra, is expected to grow at a CAGR of 4.80% and reach USD 2,096.19 million by 2028, driven by increasing prevalence of erectile dysfunction and rising healthcare expenditure. For more information about Sandoz and its role in the generics market, visit their official website.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories, although not specifically known for producing Viagra, is a prominent player in the global pharmaceutical industry, particularly in the generics segment. The company has a strong track record of developing and marketing affordable drugs, including generics and biosimilars. In FY2024, Dr. Reddy's Laboratories achieved a significant revenue growth of 14% to Rs279.2 billion, driven largely by its global generics segment, which saw a 15% year-over-year growth. The company has expanded its presence globally, with operations in 56 countries and a workforce of over 23,000 employees. However, it does not specialize in Viagra, which is a brand owned by Pfizer. For more information about their products and services, visit the official Dr. Reddy's website.